{
    "nctId": "NCT01462604",
    "briefTitle": "Pilot Study of Patient's Adherence to TYKERB\u2122/TYVERB\u2122 + Capecitabine in Metastatic Breast Cancer",
    "officialTitle": "PROACTYVE Pilot:Pilot Study of Patient's Adherence to TYKERB\u2122/TYVERB\u2122+Capecitabine in Metastatic Breast Cancer-Observation of Patient Adherence and Evaluation of Predictive Factors for Patient Adherence After Providing Educational Programme",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "Subject recruitment and retention in the study",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed written informed consent;\n2. Female outpatient aged 18 years or older;\n3. Subjects must be about to begin their initial treatment with lapatinib + capecitabine for HER2+ metastatic or advanced breast cancer according to physician's clinical judgement as per local prescribing information\n4. Subjects must be literate, be able to read, understand and write local language.\n\nExclusion Criteria:\n\n1. Women who is participating in any other interventional clinical trials concurrently;\n2. Women who is already taking or had taken lapatinib + capecitabine regimen prior to the enrollment;\n3. Primary lesions that are not of breast origin.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}